AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CRISPR Therapeutics AG Director's Dealing 2018

Jun 16, 2018

30936_dirs_2018-06-15_ed7ce327-fb36-45b8-af27-b660583f73a6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2018-06-15

Reporting Person: Kulkarni Samarth (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-15	Stock Option (Right to Buy)	$59.31	A	109000	Acquired	2028-06-15	Common Shares (109000)	Direct

Footnotes

F1: This option was granted on June 15, 2018 with respect to 109,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments.